Infections in India hit another grim daily record on Thursday as demand for medical oxygen jumped sevenfold and the government denied reports that it was slow in distributing life-saving supplies from abroad.
The number of new confirmed cases breached 400,000 for the second time since the devastating surge began last month. The 412,262 new cases pushed India’s official tally to more than 21 million. The Health Ministry also reported 3,980 deaths in the last 24 hours, bringing the total to 230,168. Experts believe both figures are an undercount.
Eleven COVID-19 patients died when the pressure in an oxygen line dropped suddenly in a government medical college hospital in Chengalpet in southern India on Wednesday night, possibly because of a faulty valve, The Times of India newspaper reported.
Hospital authorities said they repaired the pipeline last week, but the consumption of oxygen had doubled since then, the newspaper said.
Demand for hospital oxygen has increased sevenfold since last month, a government official said, as India scrambles to set up large oxygen plants and transport oxygen. India created a sea bridge on Tuesday to ferry oxygen tankers from Bahrain and Kuwait in the Persian Gulf, officials said.
Most hospitals in India aren’t equipped with independent plants that generate oxygen directly for patients, As a result, hospitals typically rely on liquid oxygen, which can be stored in cylinders and transported in tankers. But amid the surge, supplies in hard-hit places such as New Delhi are running critically short.
Health Minister Harsh Vardhan said India has enough liquid oxygen but it’s facing capacity constraints in moving it. Most oxygen is produced in the eastern parts of India while the demand has risen in northern and western parts.
K. Vijay Raghvan, a principal scientific adviser to the government, said this phase of the pandemic was “a very critical time for the country.”
The United States, Britain, Germany and several other nations are rushing therapeutics, rapid virus tests and oxygen, along with materials needed to boost domestic production of COVID-19 vaccines to ease pressure on the fragile health infrastructure.
India’s vaccine production is expected to get a boost with the United States supporting a waiver of intellectual property protections for COVID-19 vaccines.
Vaccine components from the U.S. that have arrived in India will enable the manufacturing of 20 million doses of AstraZeneca vaccine, said Daniel B. Smith, the senior diplomat at the U.S. Embassy in New Delhi.
Last month, Adar Poonawalla, chief executive officer of the Serum Institute of India, the world’s biggest vaccine maker, appealed to President Joe Biden to lift the embargo on U.S. export of raw materials, which he said was affecting its production of COVID-19 shots.
The government meanwhile described as “totally misleading” Indian media reports that it took seven days to come up with a procedure for distributing urgent medical supplies that started arriving on April 25.
The statement sad a streamlined and systematic mechanism for allocation of the supplies received by India has been put in place for effective distribution. The Indian Red Cross Society is involved in distributing supplies from abroad, it said.
READ ALSO:
